PolyPid Provides Corporate Update and Reports Fourth Quarter

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway

Related Keywords

Israel , Dafna , Ha Afon , Dikla Czaczkes Akselbrad , Brian Ritchie , Czaczkes Akselbrad , Company Annual Report On Form , Twitter , Polypid Ltd , Linkedin , Fund Polypid , Nasdaq , More Than , Abdominal Colorectal Surgical Site , Interim Analysis , Conducted Once Approximately , Complete Their , Day Follow Up , Top Line Results Expected , Second Half , Intratumorally Reduced Tumor Volume , Improved Survival , New Animal , Financing Extends Company , Cash Runway Through Late Third Quarter , Beyond Expected Timing , Unblinded Interim Analysis , Potential Additional , Planned New Drug Application Submission , Call Scheduled , Corporate Highlights , New Drug Application , Chief Executive , Call Dial In , Webcast Information , Polymer Lipid Encapsulation , Active Pharmaceutical Ingredients , Private Securities Litigation Reform Act , Annual Report , Polypid , The Company , Financial Results , Business Development ,